ArticleMicrobial genomics2018
Multi-clonal evolution of multi-drug-resistant/extensively drug-resistant Mycobacterium tuberculosis in a high-prevalence setting of Papua New Guinea for over three decades.
Article in Microbial genomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Reporting practices for genomic epidemiology of tuberculosis: a systematic review of the literature using STROME-ID guidelines as a benchmark.The Lancet. Microbe · 2021Pooled it
- Inference of Multiple Mergers while Dating a Pathogen Phylogeny.Systematic biology · 2025Article
- TB programme outcomes in South Fly District, Papua New Guinea, were maintained through COVID-19.Public health action · 2024Article
- Continuous quality improvement in a community-wide TB screening and prevention programme in Papua New Guinea.Public health action · 2024Article
- Sustained transmission over two decades of a previously unrecognised MPT64 negativeThe Lancet regional health. Western Pacific · 2024Article
- Loss-of-function mutations inAntimicrobial agents and chemotherapy · 2024Article
- Genetic diversity, evolution and drug resistance ofFrontiers in microbiology · 2024Review
- Article
- The role and value of counsellors in the treatment journeys of people with tuberculosis and their families: Qualitative insights from the South Fly District of Papua New Guinea.PLOS global public health · 2024Article
- Genomic Characterization of Drug-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Drug resistance prediction forMicrobial genomics · 2023Article
- Distribution and origins ofMicrobial genomics · 2023Article
- Paediatric formulations for the treatment of drug resistant TB: closing the gaps.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2022Article
- Review
- Evolution and spread of a highly drug resistant strain of Mycobacterium tuberculosis in Papua New Guinea.BMC infectious diseases · 2022Article
- Transmission, distribution and drug resistance-conferring mutations of extensively drug-resistant tuberculosis in the Western Cape Province, South Africa.Microbial genomics · 2022Article
- Article
- Review
- Clinical and public health utility of Mycobacterium tuberculosis whole genome sequencing.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Article
- Genomic epidemiology of tuberculosis in eastern Malaysia: insights for strengthening public health responses.Microbial genomics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An outbreak of multi-drug resistant (MDR) tuberculosis (TB) has been reported on Daru Island, Papua New Guinea. Mycobacterium tuberculosis strains driving this outbreak and the temporal accrual of drug resistance mutations have not been described. Whole genome sequencing of 100 of 165 clinical isolates referred from Daru General Hospital to the Supranational reference laboratory, Brisbane, during 2012-2015 revealed that 95 belonged to a single modern Beijing sub-lineage strain. Molecular dating suggested acquisition of streptomycin and isoniazid resistance in the 1960s, with potentially enhanced virulence mediated by an mycP1 mutation. The Beijing sub-lineage strain demonstrated a high degree of co-resistance between isoniazid and ethionamide (80/95; 84.2 %) attributed to an inhA promoter mutation combined with inhA and ndh coding mutations. Multi-drug resistance, observed in 78/95 samples, emerged with the acquisition of a typical rpoB mutation together with a compensatory rpoC mutation in the 1980s. There was independent acquisition of fluoroquinolone and aminoglycoside resistance, and evidence of local transmission of extensively drug resistant (XDR) strains from 2009. These findings underline the importance of whole genome sequencing in informing an effective public health response to MDR/XDR TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.